BioNexus Gene Lab (BGLC) Cost of Revenue (2018 - 2026)

BioNexus Gene Lab's Cost of Revenue history runs 9 years deep, the most recent figure standing at $52733.0 for Q1 2026.

• In Q1 2026, Cost of Revenue fell 97.06% year-over-year to $52733.0; the TTM figure through Mar 2026 stood at $3.3 million (up 514.23% YoY), while the FY2025 annual figure was $6.3 million, up 212.2% from the prior year.
• Cost of Revenue came in at $52733.0 for Q1 2026 at BioNexus Gene Lab, down from $487743.0 in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $2.7 million in Q1 2022 to a low of -$4.0 million in Q4 2024.
• A 5-year average of $1.3 million and a median of $2.0 million in 2023 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue plunged 298.15% in 2024 and surged 345.75% in 2025, its largest moves.
• BioNexus Gene Lab's Cost of Revenue stood at $2.5 million in 2022, then dropped by 19.75% to $2.0 million in 2023, then slumped by 298.15% to -$4.0 million in 2024, then surged by 112.27% to $487743.0 in 2025, then slumped by 89.19% to $52733.0 in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $52733.0, $487743.0, and $2.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison